About
Technology
Issues
FAQ
Links
Official Page
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.